Crossmark

Profiling the proximal proteome of the activated μ-opioid receptor

Crossref DOI link: https://doi.org/10.1038/s41589-024-01588-3

Published Online: 2024-03-25

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Polacco, Benjamin J. https://orcid.org/0000-0003-1570-9234
Lobingier, Braden T.

Blythe, Emily E. https://orcid.org/0000-0001-6363-2644
Abreu, Nohely https://orcid.org/0000-0002-6733-7607
Khare, Prachi

Howard, Matthew K. https://orcid.org/0000-0002-2128-2065
Gonzalez-Hernandez, Alberto J. https://orcid.org/0000-0002-2817-2475
Xu, Jiewei

Li, Qiongyu

Novy, Brandon

Naing, Zun Zar Chi

Shoichet, Brian K. https://orcid.org/0000-0002-6098-7367
Coyote-Maestas, Willow

Levitz, Joshua https://orcid.org/0000-0002-8169-6323
Krogan, Nevan J. https://orcid.org/0000-0003-4902-337X
Von Zastrow, Mark https://orcid.org/0000-0003-1375-6926
Hüttenhain, Ruth https://orcid.org/0000-0002-0896-5910
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA043607, R01DA056354, R01DA010711, DA012864, R01DA056354)

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (K99GM151441, R35GM124731, 5T32GM139786)

United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-19-2-0020, HR0011-19-2-0020, HR0011-20-2-0029, HR0011-19-2-0020)

Rohr Family Research Scholar Award Irma T. Hirschl and Monique Weill-Caulier Award

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL146366)

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (1U01MH115747, 1U01MH115747, MH120212)

Margarita Salas Fellowship from the Spanish Ministry of Universities
License Information

Text and Data Mining valid from 2024-03-25

Version of Record valid from 2024-03-25
More Information

Article History

Received: 27 July 2022

Accepted: 22 February 2024

First Online: 25 March 2024

Competing interests

: The Krogan laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. has financially compensated consulting agreements with Maze Therapeutics and Interline Therapeutics. He is on the Board of Directors and is President of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, GEn1E Lifesciences and Interline Therapeutics. B.K.S. is a founder of Epiodyne Inc., BlueDolphin LLC and Deep Apple Therapeutics, serves on the SAB of Schrodinger LLC and of Vilya Therapeutics, on the SRB of Genentech, and consults for Levator Therapeutics, Hyku Therapeutics and Great Point Ventures. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below